Application of non‐invasive bioreactance to assess hemodynamic function in patients with hypertrophic cardiomyopathy
Physiological Reports · 2023
DOI: 10.14814/phy2.15729 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Reports, 2023. Verfasst von Nduka Charles Okwose und 7 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme.
Abstract (Originalsprache)
Non‐invasive technologies have become popular for the clinical evaluation of cardiac function. The present study evaluated hemodynamic response to cardiopulmonary exercise stress testing using bioreactance technology in patients with hypertrophic cardiomyopathy. The study included 29 patients with HCM (age 55 ± 15 years; 28% female) and 12 age (55 ± 14 years), and gender matched (25% female) healthy controls. All participants underwent maximal graded cardiopulmonary exercise stress testing with simultaneous non‐invasive hemodynamic bioreactance and gas exchange. At rest, patients with HCM demonstrated significantly lower cardiac output (4.1 ± 1.3 vs. 6.1 ± 1.2 L/min; p < 0.001), stroke volume (61.5 ± 20.8 vs. 89.5 ± 19.8 mL/beat; p < 0.001), and cardiac power output (0.97 ± 0.3 vs. 1.4 ± 0.3watt; p < 0.001), compared to controls. At peak exercise, the following hemodynamic and metabolic variables were lower in HCM patients that is, heart rate (118 ± 29 vs. 156 ± 20 beats/min; p < 0.001), cardiac output (15.5 ± 5.8 vs. 20.5 ± 4.7 L/min; p = 0.017), cardiac power output (4.3 ± 1.6 vs. 5.9 ± 1.8 watts; p = 0.017), mean arterial blood pressure (126 ± 11 vs. 134 ± 10 mmHg; p = 0.039), and oxygen consumption (18.3 ± 6.0 vs. 30.5 ± 8.3 mL/kg/min; p < 0.001), respectively. Peak arteriovenous oxygen difference and stroke volume were not significantly different between HCM patients and healthy controls (11.2 ± 6.4 vs. 11.9 ± 3.1 mL/100 mL, p = 0.37 and 131 ± 50.6 vs. 132 ± 41.9 mL/beat, p = 0.76). There was a moderate positive relationship between peak oxygen consumption and peak heart rate ( r = 0.67, p < 0.001), and arteriovenous oxygen difference ( r = 0.59, p = 0.001). Functional capacity is significantly reduced in patients with HCM primarily due to diminished central (cardiac) rather than peripheral factors. Application of non‐invasive hemodynamic assessment may improve understanding of the pathophysiology and explain mechanisms of exercise intolerance in hypertrophic cardiomyopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
- Research Centre for Health and Life Sciences, Institute for Health and Wellbeing, Faculty of Health and Life Sciences, Coventry University, Coventry, UK.
- Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University, Newcastle upon Tyne, UK.
ORCID-Profile: Djordje G Jakovljevic
Förderung
- Horizon 2020 Framework Programme
Zitieren
APA
Okwose, N. C., Fuller, A. S., Alyahya, A. I., Charman, S. J., Eggett, C., Luke, P., MacGowan, G. A., & Jakovljevic, D. G. (2023). Application of non‐invasive bioreactance to assess hemodynamic function in patients with hypertrophic cardiomyopathy. Physiological Reports. https://doi.org/10.14814/phy2.15729
Vancouver
Okwose NC, Fuller AS, Alyahya AI, Charman SJ, Eggett C, Luke P, et al. Application of non‐invasive bioreactance to assess hemodynamic function in patients with hypertrophic cardiomyopathy. Physiological Reports. 2023. doi:10.14814/phy2.15729
BibTeX
@article{Okwose2023,
author = {Okwose, Nduka Charles and Fuller, Amy S and Alyahya, Alaa I and Charman, Sarah J and Eggett, Christopher and Luke, Peter and MacGowan, Guy A and Jakovljevic, Djordje G},
title = {Application of non‐invasive bioreactance to assess hemodynamic function in patients with hypertrophic cardiomyopathy},
journal = {Physiological Reports},
year = {2023},
doi = {10.14814/phy2.15729}
}
EUVIMED